JP2003532640A5 - - Google Patents

Download PDF

Info

Publication number
JP2003532640A5
JP2003532640A5 JP2001574119A JP2001574119A JP2003532640A5 JP 2003532640 A5 JP2003532640 A5 JP 2003532640A5 JP 2001574119 A JP2001574119 A JP 2001574119A JP 2001574119 A JP2001574119 A JP 2001574119A JP 2003532640 A5 JP2003532640 A5 JP 2003532640A5
Authority
JP
Japan
Prior art keywords
apomorphine
patient
norapomorphine
administering
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001574119A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003532640A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/040393 external-priority patent/WO2001076602A1/en
Publication of JP2003532640A publication Critical patent/JP2003532640A/ja
Publication of JP2003532640A5 publication Critical patent/JP2003532640A5/ja
Withdrawn legal-status Critical Current

Links

JP2001574119A 2000-04-07 2001-03-29 アポモルヒネ誘導体及びその使用方法 Withdrawn JP2003532640A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19565000P 2000-04-07 2000-04-07
US60/195,650 2000-04-07
PCT/US2001/040393 WO2001076602A1 (en) 2000-04-07 2001-03-29 Apomorphine derivatives and methods for their use

Publications (2)

Publication Number Publication Date
JP2003532640A JP2003532640A (ja) 2003-11-05
JP2003532640A5 true JP2003532640A5 (https=) 2005-05-26

Family

ID=22722192

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001574119A Withdrawn JP2003532640A (ja) 2000-04-07 2001-03-29 アポモルヒネ誘導体及びその使用方法

Country Status (18)

Country Link
US (1) US6506765B2 (https=)
EP (1) EP1284735A4 (https=)
JP (1) JP2003532640A (https=)
KR (1) KR20030036157A (https=)
CN (1) CN1471395A (https=)
AU (1) AU2001255818A1 (https=)
BG (1) BG107217A (https=)
BR (1) BR0109515A (https=)
CA (1) CA2405419A1 (https=)
CZ (1) CZ20023637A3 (https=)
HU (1) HUP0301773A3 (https=)
IL (1) IL151614A0 (https=)
MX (1) MXPA02009904A (https=)
NO (1) NO20024806D0 (https=)
PL (1) PL361672A1 (https=)
SK (1) SK15772002A3 (https=)
WO (1) WO2001076602A1 (https=)
ZA (1) ZA200207489B (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102036D0 (sv) * 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
SE0002934D0 (sv) * 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
CA2446904A1 (en) * 2001-05-24 2003-04-03 Alexza Pharmaceuticals, Inc. Delivery of drug esters through an inhalation route
KR20050008658A (ko) * 2002-03-19 2005-01-21 마이클 홀릭 아포모르핀의 글리코시드 및 오르토에스테르 글리코시드유도체들, 유사체들 및 그것의 용도
WO2004069167A2 (en) * 2003-01-31 2004-08-19 Nastech Pharmaceutical Company Inc. Method and compositions for treating male infertility
RU2364400C2 (ru) * 2003-04-14 2009-08-20 Вектура Лтд Фармацевтические композиции
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
ES3012497T3 (en) 2005-10-12 2025-04-09 Besins Healthcare Lu Sarl Improved testosterone gel and method of use
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
JP7320507B2 (ja) 2017-11-24 2023-08-03 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
EP3972971A1 (en) 2019-05-21 2022-03-30 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's diseases
CN113727712B (zh) 2019-05-21 2024-11-15 H.隆德贝克有限公司 用于治疗帕金森病的儿茶酚胺氨基甲酸酯前药
WO2020234274A1 (en) 2019-05-21 2020-11-26 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
JP7562562B2 (ja) 2019-05-21 2024-10-07 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
WO2023012736A1 (en) * 2021-08-05 2023-02-09 Zydus Lifesciences Limited Stable pharmaceutical compositions of apomorphine

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4127118B1 (en) 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
US4801587A (en) 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5256652A (en) 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
DE69434304T2 (de) 1993-03-26 2005-12-29 Merkus, Franciscus Wilhelmus H.M. Pharmazeutische Zusammensetzungen zur intranasalen Verabreichung von Dihydroergotamin
JP3310982B2 (ja) 1994-04-22 2002-08-05 ペンテツク・フアーマシユーテイカルズ・インコーポレイテツド 男性の勃起機能不全を改善するための剤形及び方法
US5562917A (en) 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5888534A (en) 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
EP0914097B1 (en) 1996-03-12 2002-01-16 Alza Corporation Composition and dosage form comprising opioid antagonist
GB9700878D0 (en) 1997-01-17 1997-03-05 Scherer Ltd R P Dosage forms and method for ameliorating male erectile dysfunction
US5925629A (en) * 1997-10-28 1999-07-20 Vivus, Incorporated Transurethral administration of androgenic agents for the treatment of erectile dysfunction
WO1999027905A1 (en) 1997-12-02 1999-06-10 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Compositions for nasal administration
US5945117A (en) 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
AU4254799A (en) * 1998-06-22 2000-01-10 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
IT1299566B1 (it) * 1998-07-17 2000-03-16 Ifi Istituto Farmacoterapico I Cerotto transdermico e composizioni farmaceutiche comprendenti r (-)- norapropilapomorfina cloridrato e/o s (+) - norapropilapomorfina
US5994363A (en) 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
WO2000069416A1 (en) * 1999-05-13 2000-11-23 Unihart Corporation Pharmaceutical compositions comprising apocodeine and/or its derivatives

Similar Documents

Publication Publication Date Title
JP2003532640A5 (https=)
JP2021063088A5 (https=)
JP2005526107A5 (https=)
JP2003501488A5 (https=)
JP2003535094A5 (https=)
JP2012525393A5 (https=)
JP2019515908A5 (https=)
IL176107A0 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
JP2001525359A5 (https=)
SG169233A1 (en) Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
MXPA01006474A (es) Derivados colquinol como agentes perjudiciales vasculares.
JP2002363097A5 (https=)
JP2004525142A5 (https=)
JP2002508361A5 (https=)
JP2008523098A5 (https=)
JP2004534769A5 (https=)
JP2003509349A5 (https=)
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
JP2020507589A5 (https=)
JP2001526218A5 (https=)
JP2005525991A5 (https=)
JP2003520208A5 (https=)
JP2002506864A5 (https=)
JP2002509154A5 (https=)
JP2012504584A5 (https=)